Traitements innovants en toxicomanie


Modulation of ∆9-tetrahydrocannabinol acute psychoactive effects by ranging doses of cannabidiol in healthy, occasional cannabis users: a controlled, triple blind, randomized, cross-over study


20 months


Coming soon in 2023


Aged between 21 and 49

Traitements innovants en toxicomanie

Comprehension Project

Study on the factors that influence cannabis use among people with psychosis and its impacts on their life and their family. 

Approximately 1.5h for one group discussion or 1h for an individual interview.

Monetary compensation proportional to duration.




Group A participants :    

Have experienced or are experiencing psychosis, aged between 16 and 65, have used cannabis regularly in the last 12 months.  

Group B participants:    

Have a relative who has experienced or is experiencing psychosis and who has used cannabis, aged between 16 and 65. 

Your role

Fill in questionnaires to assess your eligibility, take part in a discussion session or an interview to give your perspective on your consumption or the consumption of your loved one. 

Traitements innovants en toxicomanie


INGESTED cannabidiol study:
Approximately 7h/ visit. Monetary compensation proportional to the duration.

Ended in summer 2023

Participants invited:
Healthy, between the ages of 21 and 65, have used cannabis at least once in your life and are currently an occasional cannabis user.

Your role:
Attend a visit to evaluate your eligibility, take blood samples, complete questionnaires, perform procedures specific to the study project, and consume cannabidiol on site as directed.